相关实验视频
Updated: Sep 15, 2025
08:48
Author Spotlight: Decoding Mitochondrial Aging
Published on: June 30, 2023
4.2K
神经退行性疾病中的线粒体功能障碍:原型向药物输送解决方案的作用
1University Institute of Pharma Sciences, Chandigarh University, Gharuan, Mohali (140413), India.
Current drug safety
|July 15, 2025
概括
用新型药物输送系统准线粒体为阿尔茨海默氏症和帕金森氏症等神经退行性疾病提供了一个有前途的治疗策略. 这种方法旨在恢复线粒体功能并对抗神经元退化.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
背景情况:
- 线粒体功能障碍是神经退行性疾病的关键因素,如阿尔茨海默氏病 (AD),帕金森病 (PD),亨廷顿病 (HD) 和肌缩侧面硬化症 (ALS).
- 需要有效的治疗策略来解决神经元退化和在这些条件下维护线粒体功能.
研究的目的:
- 为提供针对神经退行性疾病中线粒体功能障碍的向药物输送近期进展的全面审查.
- 探索在AD,PD,HD和ALS中线粒体功能障碍的机制,并确定治疗干预机会.
主要方法:
- 对新兴药物递送技术的审查,包括线粒体响应系统,纳米颗粒,和病毒载体.
- 对针对线粒体的治疗药物的疗效和安全性进行临床前和临床研究的分析.
- 在特定的神经退行性疾病中探索线粒体功能障碍的潜在机制.
主要成果:
- 最近的进展突出了各种药物输送系统的潜力,可以直接准线粒体.
- 线粒体反应系统,纳米颗粒,和病毒载体在提供治疗剂方面表现有前途.
- 目前正在收集临床前和临床数据,以评估这些向方法的有效性和安全性.
结论:
- 针对线粒体的向药物输送代表了神经退行性疾病的重要治疗途径.
- 在线粒体生物学和药物输送的交叉点进行进一步的研究和创新对于开发有效的治疗方法至关重要.
- 解决线粒体功能障碍有望缓解AD,PD,HD和ALS的神经元退化.
相关概念视频
01:46Electron Transport Chain: Complex I and II
15.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
15.0K
01:15Parkinson's Disease: Overview
715
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
715
01:29Drugs Affecting Neurotransmitter Synthesis
1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
01:19Translocation of Proteins into the Mitochondria
3.3K
Mitochondrial precursors are translocated to the internal subcompartments via independent mechanisms involving distinct protein machineries called translocases.
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
3.3K
01:24Parkinson's Disease: Treatment
385
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
385
01:22Alzheimer's Disease: Treatment
263
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
263